Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non‐syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma
Authors:
Open Access
- 16 October 2012
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 78 (6) , 898-906
Abstract
Summary: Objectives: Research studies have reported that about a third of individuals with phaeochromocytoma/paraganglioma (PPGL) have an inherited predisposition, although the frequency of specific mutations can vary between populations. We evaluated VHL, SDHB and SDHD mutation testing in cohorts of patients with non‐syndromic PPGL and head and neck paraganglioma (HNPGL).Design: Prospective, observational evaluation of NHS practice.Patients: Individuals with PPGL/HNPGL referred to a supraregional genetics testing service over a 10‐year period.Measurements: Clinical (age, tumour site, malignancy, etc.), mutation frequencies and characteristics.Results: A total of 501 probands with PPGL (n = 413) or HNPGL (n = 88) were studied. Thirty‐one percent of patients with PPGL presented had a pathogenic mutation in SDHB, SDHD or VHL. Mutation detection rates were highest in those with a positive family history (62%), malignancy (53%), multiple tumours (33%) or PGL (44%). Twenty‐eight percent of individuals with a single sporadic phaeochromocytoma had a mutation. Overall, 63% of patients with HNPGL had a mutation (92% of those with a family history, 89% of those with multicentric tumours and 34% of those with a single sporadic HNPGL). Penetrance was calculated in 121 SDHB mutation‐positive probands and 187 of their mutation‐positive relatives. Most relatives were asymptomatic and lifetime penetrance in non‐proband SDHB mutation carriers was <50%.Conclusions: Practice‐based evaluations of genetic testing in PPGL reveal high mutation detection rates. Although clinical criteria can be used to prioritize mutation testing, mutations were detected in ‘low risk groups’ indicating a need for comprehensive and inexpensive genetic testing strategies for PPGL and HNPGL.Keywords
This publication has 38 references indexed in Scilit:
- GENETICS IN ENDOCRINOLOGY: The genetics of phaeochromocytoma: using clinical features to guide genetic testingEuropean Journal of Endocrinology, 2012
- High prevalence of founder mutations of the succinate dehydrogenase genes in the NetherlandsClinical Genetics, 2011
- Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations inSDHBandSDHDHuman Mutation, 2009
- Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma PatientsClinical Cancer Research, 2009
- The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with ParagangliomasThe Journal of Clinical Endocrinology & Metabolism, 2009
- Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-OutCancer Research, 2009
- Germ-Line Mutations in Nonsyndromic PheochromocytomaNew England Journal of Medicine, 2002
- Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial ParagangliomaThe American Journal of Human Genetics, 2001
- Germline SDHD mutation in familial phaeochromocytomaThe Lancet, 2001
- Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effectHuman Genetics, 1995